Skip to content

Becton Dickinson & Co

US · BDX #450 by market cap Listed 1970
212.78 +0.10 +0.05%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Official SEC filings

Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 02:43 UTC.

FormFiledOriginal document
8-K2026-11-05Read on SEC.gov
10-Q2026-08-06Read on SEC.gov
8-K2026-08-06Read on SEC.gov
8-K2026-07-22Read on SEC.gov
8-K2026-05-29Read on SEC.gov
8-K2026-05-20Read on SEC.gov
8-K2026-05-12Read on SEC.gov
10-Q2026-05-07Read on SEC.gov

SEC annual financial snapshot

Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-21 17:51 UTC.

MetricUSDBasisPeriod endFiledSource
Revenue$21.84BAnnual2025-09-302025-11-2510-K
Net income$1.68BAnnual2025-09-302025-11-2510-K
Total assets$55.33BAs of2025-09-302025-11-2510-K
Stockholders’ equity$25.39BAs of2025-09-302025-11-2510-K
Cash and cash equivalents$641.00MAs of2025-09-302025-11-2510-K

✦ Quant Revenue Concentration how this is computed

Diversified
  • Medical Essentials is the largest reported line at 33.61% of revenue, across 4 reported segments.
  • No single line clears half of revenue; Interventional is next at 28.38%, spreading the business across more than one real driver.

Revenue annual, last 8 years

Latest year -10.91% YoY

Margins

Gross margin
47.36%
Operating margin
15.74%
Net margin
5.88%

Key ratios & quality

Income statement

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Revenue 17.29B16.07B19.13B18.87B19.37B20.18B21.84B19.46B
Gross profit 8.29B6.80B8.63B8.48B8.17B9.13B9.93B9.21B
Selling & admin expenses 4.33B4.19B4.72B4.71B4.72B4.86B5.28B4.97B
Research & development 1.06B1.04B1.28B1.26B1.24B1.19B1.27B988.00M
Operating profit 2.24B1.21B2.43B2.48B2.42B2.86B2.99B3.06B
Pretax profit 1.18B414.00M1.69B1.78B1.66B2.01B1.88B1.81B
Tax -57.00M62.00M88.00M148.00M132.00M300.00M203.00M388.00M
Net profit 1.23B874.00M2.09B1.78B1.48B1.71B1.68B1.15B
Basic EPS 43765664
Diluted EPS 3.942.716.855.884.945.865.824.09

Balance sheet

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Total current assets 6.66B8.97B8.84B8.14B8.68B10.47B9.26B8.32B
Cash & ST investments 566.00M2.85B2.30B1.01B1.42B2.16B649.00M733.00M
Inventory 2.58B2.74B2.74B3.22B3.27B3.84B3.89B3.19B
Total assets 51.77B54.01B53.88B52.93B52.78B57.29B55.33B50.79B
Total current liabilities 5.66B5.84B6.63B7.81B6.64B8.96B8.31B9.54B
Short-term debt 1.31B706.00M500.00M2.18B1.14B2.17B1.56B2.92B
Long-term debt 18.08B17.22B17.11B13.89B14.74B17.94B17.62B13.42B
Total liabilities 30,683,000,000.0030,247,000,000.0030,203,000,000.0027,652,000,000.0026,983,000,000.0031,397,000,000.0029,935,000,000.0026,109,000,000.00
Total equity 21.08B23.77B23.68B25.28B25.80B25.89B25.39B24.68B
Retained earnings 12.91B12.79B13.83B15.16B15.54B16.14B16.62B--

Cash flow

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Operating cash flow 3.33B3.54B4.65B2.63B2.99B3.80B3.43B3.37B
Depreciation & amortization 2.25B2.12B2.23B2.23B2.29B2.29B2.46B2.24B
Free cash flow 2.37B2.77B3.45B1.66B2.12B3.07B2.67B2.69B
Dividends paid -984.00M-1.03B-1.05B-1.08B-1.11B-1.10B-1.20B-1.16B
Stock buybacks / issuance 02.92B-1.75B-500.00M0-500.00M-1.00B-2.43B
Ending cash balance 590.00M2.92B2.39B1.16B1.48B1.86B851.00M1.01B

Returns & efficiency

Line item 2019 2020 2021 2022 2023 2024 2025 2026
ROE % 5.143.428.446.905.586.606.544.57
ROA % 2.051.453.713.162.693.102.982.16
ROIC % 3.712.995.864.944.324.604.843.66
5-year avg ROE % 8.136.545.594.975.906.196.81--
EBIT margin % 10.508.8413.3911.5610.9112.5511.4212.18
FCF / sales % 13.7115.9416.878.8010.9215.2212.2313.85
Current ratio 1.181.541.331.041.311.171.110.87
Quick ratio 0.510.900.700.410.600.580.440.37
Debt / assets 37.4633.2032.6830.3530.0935.1034.6732.18
LT debt / equity 85.7772.4872.2754.9357.1369.3069.4054.38
Interest coverage 2.842.875.785.484.684.804.074.20
Revenue CAGR (3Y) % 11.479.956.182.966.421.794.990.15
Net income CAGR (3Y) % 8.10-7.3888.7713.0019.30-6.59-1.93-8.28
FCF CAGR (3Y) % 8.3414.9620.58-11.23-8.60-3.8317.188.40

Revenue breakdown most recent period

Business

Medical Essentials33.61%
Interventional28.38%
Connected Care24.56%
BioPharma Systems13.45%

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Becton Dickinson & Co discussion 0 comments

Add a comment